Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Seelos Therapeutics (Nasdaq: SEEL) announced the initiation of its Expanded Access Program (EAP) for patients with Amyotrophic Lateral Sclerosis (ALS) who do not qualify for existing clinical trials. Funded by a NINDS grant under the ACT for ALS, the program aims to enroll 70 patients over 24 weeks to evaluate SLS-005. This investigational treatment is designed to stabilize proteins and activate autophagy. The CEO expressed gratitude for community support and emphasized the importance of the EAP for ALS patients lacking other therapy options. The ongoing Phase II/III study on the HEALEY ALS Platform will run concurrently.
Seelos Therapeutics (Nasdaq: SEEL) provided an update on March 29, 2023, focusing on its clinical programs. The company is temporarily pausing patient enrollment in the SLS-005-302 study for spinocerebellar ataxia type 3 (SCA3) due to financial considerations, although current participants will continue in the study. Seelos aims to concentrate resources on the SLS-002 study for Acute Suicidal Ideation and Behavior with expected data readout by Q3 2023, and the SLS-005 study for ALS data in late 2023. Seelos' corporate structure allows for strategic flexibility while extending its cash runway for upcoming data readouts.
Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced a registered direct offering of 12,059,298 shares of common stock and warrants for 26,750,000 shares at a price of $0.525 per share, expected to raise approximately $11.24 million. The offering includes pre-funded warrants exercisable for 9,340,702 shares at $0.001 per share. The proceeds will be used for general corporate purposes and development of product candidates. Closing is anticipated on or about March 14, 2023. The offering is made under an effective shelf registration statement with the SEC.
Seelos Therapeutics, Inc. (NASDAQ: SEEL) announced its participation in the 43rd Annual Cowen Health Care Conference happening in Boston, Massachusetts from March 6-8, 2023. CEO Raj Mehra and senior management will host meetings during the event. Seelos is focused on developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions like Acute Suicidal Ideation in Major Depressive Disorder and various neurodegenerative diseases including ALS and Huntington’s disease. For more details, visit their website.